# Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock

> **NCT05969275** · PHASE2 · RECRUITING · sponsor: **Ottawa Hospital Research Institute** · enrollment: 296 (estimated)

## Conditions studied

- Septic Shock
- Sepsis
- Pathologic Processes
- Shock
- Systemic Inflammatory Response Syndrome
- Inflammation
- Infections

## Interventions

- **BIOLOGICAL:** Allogeneic umbilical cord-derived human mesenchymal stromal cells
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05969275
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-14
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-03-31
- **Target enrollment:** 296 (ESTIMATED)
- **Last updated:** 2024-12-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05969275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05969275, "Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05969275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*